α4 integrin receptor antagonist 3_product_DataBase

Bioactivity	α4 integrin receptor antagonist 3 (Compound 11) is an orally active α4 integrin receptor antagonist. α4 integrin receptor antagonist 3 (Compound 11) can inhibit the adhesion of K562 cells mediated by the interaction between α4β1/VCAM-1 and α4β7/MAdCAM-1, with IC50 values of 130 nM and 2 nM, respectively. α4 integrin receptor antagonist 3 (Compound 11) can prevent the development of colitis in DSS colitis mice[1].
Target	IC50: 130 nM, 2 nM (α4β1/VCAM-1, α4β7/MAdCAM-1)
Invitro	α4 integrin receptor antagonist 3 (Compound 11) 可以抑制 α4β1/VCAM-1 和 α4β7/MAdCAM-1 相互作用介导的 K562 细胞粘附[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> α4 integrin receptor antagonist 3 相关抗体:
In Vivo	α4 integrin receptor antagonist 3 (Compound 11) (60 mg/kg; 每天 2 次; 7 天; 口服) 可以在 DSS 结肠炎小鼠中预防结肠炎的发展[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model:
CAS	863226-74-8
Formula	C23H21Cl2N3O6
Molar Mass	506.34
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Gong Y, et al. Synthesis and biological evaluation of novel pyridazinone-based alpha4 integrin receptor antagonists. J Med Chem. 2006 Jun 1;49(11):3402-11.

PeptideDB